UK-based company Genomics has entered a collaborative deal with US-based biotechnology firm Biogen to discover new treatments for multiple sclerosis (MS).

Financial terms of the deal remain undisclosed.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Genomics focuses on the use of human genetic information to enhance all aspects of drug development.

MS is a debilitating disease, in which the insulating covers of nerve cells in the brain and spinal cord are damaged.

The damage affects the ability of parts of the nervous system to communicate, thereby resulting in a wide range of signs and symptoms, including physical, mental and sometimes psychiatric problems.

Biogen Centres of Excellence, Research and Early Development vice-president Dr Sally John said: “It is becoming clear that incorporating human genetic evidence can be extremely valuable in early drug development research.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We are excited about our partnership with Genomics; they are world leaders in the analysis of genomic data.”

Under the partnership, Genomics will deploy its platform and expertise to evaluate the genetic support for early stage Biogen MS drug targets and to discover new targets.

“It is becoming clear that incorporating human genetic evidence can be extremely valuable in early drug development research.”

The company applies in-house analytical tools and combines statistics and machine learning to obtain major biological insights that can underpin successful drug development.

Genomics’ integrated platform quantifies the effects of more than seven million genetic variants on more than 1,000 different human phenotypes.

The company’s database is based on studies of more than 4.5 million participants.

Genomics founder and chief executive officer Peter Donnelly said: “The combination of big data analytics with the growing volumes of human genetic data offers the potential to transform aspects of drug development.”

Image: Photomicrograph of a demyelinating multiple sclerosis-lesion. Photo: courtesy of Marvin 101 via Wikipedia.